Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Share-based Compensation (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Share-based Compensation readings, the most recent being $2.3 million for Q4 2025.

  • Quarterly Share-based Compensation rose 85.84% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 47.84% year-over-year, with the annual reading at $6.0 million for FY2025, 47.84% up from the prior year.
  • Share-based Compensation hit $2.3 million in Q4 2025 for Oramed Pharmaceuticals, up from $719000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.2 million in Q4 2023 and bottomed at -$2.0 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $1.6 million, with a median of $1.5 million recorded in 2021.
  • The largest annual shift saw Share-based Compensation soared 12175.0% in 2021 before it crashed 165.05% in 2023.
  • Oramed Pharmaceuticals' Share-based Compensation stood at $1.7 million in 2021, then surged by 49.01% to $2.5 million in 2022, then soared by 64.95% to $4.2 million in 2023, then crashed by 70.76% to $1.2 million in 2024, then soared by 85.84% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Share-based Compensation are $2.3 million (Q4 2025), $719000.0 (Q3 2025), and $800000.0 (Q2 2025).